Articles by Editor
Billionaire Ray Dalio Snaps Up These 3 “Strong Buy” Stocks
In the investing game, the rules may no longer apply. Billionaire hedge fund manager Ray Dalio warns that the Federal Reserve has artificially propped up markets, with traditional valuation metrics no longer telling the whole story. Further, he thinks there’s a risk that the U.S. dollar will be displaced as the global reserve currency.“The capital markets are not free markets allocating resources in the traditional ways… The economy and the markets are driven by the central banks in coordination with the central government,” Dalio explained. Even though the titan believes the unprecedented stimulus was justified, he argues these actions have …read more […]
If You Like EPS Growth Then Check Out Facebook (NASDAQ:FB) Before It's Too Late
Like a puppy chasing its tail, some new investors often chase ‘the next big thing’, even if that means buying ‘story… …read more […]
Target, Lowe’s post blowout Q2 reports, Biden accepts Dem. presidential nominee, Trump campaign sues New Jersey
Yahoo Finance’s Alexis Christoforous shares what’s making headlines Wednesday morning. …read more […]
Will the Promising Trends At GrowGeneration (NASDAQ:GRWG) Continue?
What are the early trends we should look for to identify a stock that could multiply in value over the long term… …read more […]
Mall Owner CBL Properties Expects to File for Bankruptcy
(Bloomberg) — Mall owner CBL Properties is planning to file for bankruptcy, a victim of dwindling foot traffic, shuttered retail space and rents too low to cover more than $3 billion in debt.The company said in a statement it reached an agreement with some of its creditors to hand control to holders of its unsecured notes. The company said it will keep negotiating with senior lenders and others who haven’t signed onto the deal. As currently envisioned, the “in-court process” would eliminate $900 million of debt.CBL previously warned investors it was in trouble because tenants weren’t paying their rent. The …read more […]
President Trump shows support for Oracle to buy TikTok
Oracle has emerged as a potential buyer for the U.S. operations of TikTok, and he’s gained President Trump’s support. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Dan Howley discuss. …read more […]
TJ Maxx Owner Falls as Treasure-Hunt Experience Disrupted
(Bloomberg) — TJX Cos., the owner of the T.J. Maxx and Marshalls chains, fell the most in more than four months after predicting that sales at opened stores will drop as much as 20% in the current quarter, casting doubts about its ability to lure discount-seeking shoppers back amid the pandemic.The Framingham, Massachusetts-based company expects comparable store sales — a key metric for retailers — to decline by 10% to 20% at stores that are opened in the third quarter ending in November. Second-quarter results were hit by temporary closures for almost one-third of the period, the company said. TJX …read more […]
Kamala Harris’ net worth
How much is Sen. Kamala Harris worth? Here’s what we know about the Democratic vice-presidential candidate and her husband’s finances. …read more […]
TJX Opens Back Up, But Sees ‘Open-only’ Comp Sales Slipping
The offprice giant is fortified by a $6.6 billion cash horde. …read more […]
J&J’s $6.5 Billion Momenta Pact Is Year’s Biggest Pharma Deal
(Bloomberg) — Johnson & Johnson agreed to pay $6.5 billion in cash to acquire Momenta Pharmaceuticals Inc., a maker of autoimmune-disease drugs, in the largest pharmaceutical-industry merger this year.Though the price tag falls short of some of the industry-shifting takeovers of recent years, the deal is the latest sign drug companies are looking for ways to bulk up even as the coronavirus pandemic upends other businesses.At $52.50 a share, the deal represents a premium of more than 70% to Momenta’s closing price Tuesday of $30.81. The biotechnology company had seen its shares surge 56% this year after encouraging clinical-trial data …read more […]
J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta
The deal gives J&J’s Janssen unit access to Momenta’s experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases where the immune system attacks the body. J&J hopes to get the drug approved to treat several conditions and eventually bring in blockbuster sales, as the company bulks up its pharmaceuticals unit, its largest business. Shares of Cambridge, Massachusetts-based Momenta were up 69.3% at $52.15 before the bell, just a hair’s breadth away from the offer price of $52.50. …read more […]
Calculating The Fair Value Of Qiwi plc (NASDAQ:QIWI)
How far off is Qiwi plc (NASDAQ:QIWI) from its intrinsic value? Using the most recent financial data, we’ll take a… …read more […]
Stock market news live updates: Stock futures rise after S&P 500's record close; Target and Lowe's post blowout earnings
Stock futures pointed mostly higher Wednesday morning, after the S&P 500 broke above its February highs to set a fresh record close a day earlier. …read more […]
Digital Turbine, Inc. (NASDAQ:APPS) Shares Could Be 31% Above Their Intrinsic Value Estimate
How far off is Digital Turbine, Inc. (NASDAQ:APPS) from its intrinsic value? Using the most recent financial data… …read more […]
